Chugai Pharmaceutical Co., Ltd. (FRA:CUP)

Germany flag Germany · Delayed Price · Currency is EUR
45.20
-0.77 (-1.68%)
Last updated: Dec 5, 2025, 9:59 AM CET
11.28%
Market Cap 74.94B
Revenue (ttm) 6.99B
Net Income (ttm) 2.29B
Shares Out n/a
EPS (ttm) 1.39
PE Ratio 32.76
Forward PE n/a
Dividend 1.09 (2.40%)
Ex-Dividend Date Jun 27, 2025
Volume n/a
Average Volume 30
Open 45.23
Previous Close 45.97
Day's Range 45.19 - 45.23
52-Week Range 33.02 - 53.18
Beta n/a
RSI 59.80
Earnings Date Jan 29, 2026

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 re... [Read more]

Industry Pharmaceutical Preparations
Founded 1925
Employees 5,026
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol CUP
Full Company Profile

Financial Performance

In 2024, Chugai Pharmaceutical's revenue was 1.17 trillion, an increase of 5.33% compared to the previous year's 1.11 trillion. Earnings were 387.32 billion, an increase of 19.00%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.